Genentech has received U.S. Food and Drug Administration (FDA) acceptance of a new application for Gazyva (obinutuzumab), marking a key step toward expanding the therapy’s role in the treatment of lupus.

Gazyva is a type II anti-CD20 monoclonal antibody that targets and depletes B cells, which are known to drive inflammation in autoimmune diseases such as lupus. The therapy has already been approved in the United States for the treatment of lupus nephritis, a severe complication of systemic lupus erythematosus that affects the kidneys.

The newly accepted application seeks to extend the use of Gazyva to a broader lupus population, reflecting growing interest in B-cell–targeting therapies as a strategy to manage autoimmune disease activity more effectively.

The drug’s prior approval was supported by positive results from the Phase II NOBILITY and Phase III REGENCY trials, which demonstrated improved renal outcomes when Gazyva was used in combination with standard therapy. In the REGENCY study, nearly half of patients achieved a complete renal response compared to those receiving standard treatment alone, highlighting its clinical benefit.

Lupus nephritis affects a significant proportion of patients with systemic lupus erythematosus and can lead to long-term kidney damage or failure if not effectively managed. The development of therapies such as Gazyva addresses a major unmet need in this area, where treatment options have historically been limited.